

# NIH funding opportunities

29 Jan 2024 (#04)



**Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.**



See all Important Notices, Parent Announcements and Notice of Special Interest below

**Plan your application. Before starting your application attend**

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*


**To prepare an application can take *4-18 months*.**

**From submission to receiving a Notice of Award can take *10 months***

## Important Notices

[NIH revises grant review process to emphasize merit and reduce bias](#) The [NIH has revamped its grant review process](#), to create an environment where the most promising and innovative research projects receive the support they deserve. The new process focuses on scientific merit and reflects NIH's commitment to reducing reputational bias in its evaluation of grant proposals. The new [simplified framework](#) will be implemented for grant applications received on or after January 25, **2025**.

Five regulatory criteria reorganized into three factors



**[NOT-HL-24-073](#) Notice of NHLBI Participation in [PAR-22-151](#) Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional). National Heart, Lung, and Blood Institute ([NHLBI](#)) is**

interested in training programs that sustainably strengthen the HIV-associated heart, lung, blood, and sleep (HLBS) research capacity of low- and middle-income country (LMIC) institutions; train in-country experts to develop and conduct research to strengthen the HIV research capacity at the proposed LMIC institutions related to HIV-associated HLBS diseases and disorders; and maximize NHLBI's current global health investments, with the long-range goal of developing and implementing evidence-based, contextualized HIV-associated HLBS interventions to reduce the burden of chronic diseases. Multidisciplinary Training programs across the spectrum of research disciplines is encouraged, from basic biomedical, behavioral, and social science to clinical and applied sciences, including translational and implementation science that support evidence integration and emphasize the resources, context, and needs of multiple stakeholders in local settings. Training programs should include basic research skills, research design and methodology, ethics, data management and analysis, grant writing, manuscript writing, scientific presentations, as well as research administration and execution.

**[NOT-CA-24-025](#) Notice of Extension of the Expiration Date for [PAR-21-166](#) "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)".** Expiration Date is now September 08, 2025.

**[NOT-CA-24-026](#) Notice of Extension of the Expiration Date for [PAR-21- 206](#) "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)".** Expiration Date is now September 08, 2025.

**[NOT-CA-24-027](#) Notice of [National Cancer Institute](#) (NCI) Participation in [PAR-23-319](#), Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional).** The [National Cancer Institute](#) (NCI) leads, conducts, and supports research to improve cancer prevention, detection, diagnosis, treatment, and survivorship. Currently, cancer is a leading cause of premature death worldwide. Approximately one-third of global cancer deaths are attributable to behavioral risk factors, such as tobacco and alcohol use, low fruit and vegetable intake, obesity, and lack of physical activity. Predictions suggest that, by 2030, 30 million people will die from cancer each year, of whom 75% will be in low- and middle-income countries (LMICs). A key challenge to reducing the global burden of cancer in LMICs, and in other populations experiencing cancer health disparities, is the poor implementation of cancer prevention and control strategies that have been proven to work. NCI encourages applications that pursue innovative approaches to adapt, integrate, and scale-up implementation of these interventions, in accessible and affordable ways, to improve the prevention and early diagnosis of cancer in low-resource city environments. Investigators are encouraged to contact NCI Scientific/Research staff before submitting applications to discuss the match to NCI priorities.

## Parent Announcements

**[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates  
*Expiration Date: May 8, 2023. **Modified Expiration Date: May 8, 2024***

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **[PA-20-185](#)** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **[PA-20-184](#)** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **[PA-20-183](#)** Research Project Grant (Parent R01 Clinical Trial Required)
- **[PA-20-200](#)** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **[PA-20-195](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **[PA-20-194](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **[PA-20-196](#)** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Funding Opportunity (NOFO)

### 1. [PAR-24-111](#) Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed).

The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (*i.e.*, innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.

**Due dates:** June 16, 2024 through to October 16, 2026. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

### 2. [PAR-24-112](#) Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed).

The purpose of this Notice of Funding Opportunity (NOFO) is to support research that improves understanding of basic mechanisms and biomarkers of trained immunity (*i.e.*, innate immune memory), plus the functional implications of trained immunity, related to 1) immune system development and function, 2) immunity to vaccines or natural infections, or 3) allergic diseases, autoimmunity, or rejection of organ/tissue/cell transplantation.

**Due dates:** June 05, 2024 through to October 05, 2026. Due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application. The scope of the proposed project should determine the project period. The maximum project period is five years.

### 3. [RFA-FD-24-019](#) Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional. The purpose of this NOFO is to encourage new approaches to support therapeutic development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.

**Due dates:** March 25, 2024 by 11:59 PM Eastern Time.

**Budget:** The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for (2) (two) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory recipient performance. FDA /OCE intends to commit \$500,000 in FY 2024 to fund 1 award. The scope of the proposed project should determine the project period. The maximum project period is THREE (3) years.

|  |  |
|--|--|
| <p>Faculty of Medicine and Health Sciences<br/>Research &amp; Internationalisation Development &amp; Support<br/>(RIDS) &amp; Grants Management Office (GMO)<br/>009 K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.</p> | <p>Stellenbosch Campus<br/>Division for Research Development (DRD)<br/>2041 Krotoa Building, Ryneveld Street</p> |
| <p>Enquiries: <a href="mailto:cdevries@sun.ac.za">cdevries@sun.ac.za</a> / <a href="mailto:fmhsgmo@sun.ac.za">fmhsgmo@sun.ac.za</a></p>  | <p>Enquiries: <a href="mailto:research@sun.ac.za">research@sun.ac.za</a></p>                                     |
| <p>Add "Interest in NIH opportunity" in the subject line. Add the notice number in the text of the email.</p>  |  |